Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
772.70-
QQQ
717.03-
BTC/USD
80902.000.4603%
DIA
536.82-
GLD
410.87-
TLT
82.14-

ENDRA Life Sciences Inc

NDRANASDAQ
Trade with Public
Trade with Public
$5.68
At close: Sep 4, 5:00 PM EST
$6.40
0.7212.68%
After Hours: Sep 2, 5:32 PM EST
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

ENDRA Life Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for ENDRA Life Sciences (NDRA).

Price Target Range — 5 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$25Upside to Avg. PT+290.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 1, 2026Ascendiant CapitalEdward WooPT CutBuy$27→$25
Dec 8, 2025Ascendiant CapitalEdward WooPT CutBuy$38→$30
More with Benzinga EdgeGet Access

Analyst Ratings News

Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know

Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $27 to $25.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $38 to $30.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $46 to $38.
Benzinga Newsdesk

Microchip Technology To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $46

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $50 to $46.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved